Weifa ASA: Prospectus approved

Reference is made to previous stock exchange releases from Weifa ASA (the "Company") regarding the acquisition of Cederroth AS, the company that owns the Norwegian category leading intimate care brand Asan and its Swedish counterpart Sana, and the private placement to finance the acquisition.

The Norwegian Financial Supervisory Authority has today approved the prospectus dated 2 February 2016 (the Prospectus") in connection with the listing of 118,500,000 new shares on Oslo Børs.

The private placement was divided into i) a tranche 1 consisting of 79.0 million new shares (representing ~10% of the outstanding capital), and ii) a tranche 2 consisting of 39.5 million new shares (representing ~5% of the outstanding capital).

The tranche 1 shares were tradable from allocation. The tranche 2 shares were temporarily registered under a separate ISIN and will be transferred to the Company's regular ISIN and tradable upon the publication of this Prospectus.

The Prospectus will be available on the following websites:

- Weifa ASA, www.weifa.no

- Carnegie, www.carnegie.no

The Prospectus will also be made publicly available at the offices of Weifa ASA, Østensjøveien 27, N-0661 Oslo, or Carnegie, Grundingen 2, N-0106 Oslo.

For further information, please contact:

About Weifa:

Weifa is Norway's leading Consumer health company. Weifa supplies pharmaceutical products and lifestyle products that address the essential needs of consumers, customers and professional partners. The Company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux, and is also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Stock Exchange and has its head office in Oslo. In 2014, the Group had a turnover of approximately NOK 316m (after adjusting for the divestment of the B2B business). The company currently has approximately 30 employees.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.